Oxygen Inhalation TherapyPhase 1STIT-1NCT01686893
Evaluation of Safety and Efficacy of Shorttime TNI Treatment in Patients With COPD
A Phase 1 study testing Nasal oxygen insufflation with a TNI 20 oxy device and Standard Nasal Insufflation of oxygen in people with Oxygen Inhalation Therapy, run by Medical University Innsbruck at 3 sites in 3 countries.
Trial summary
Evaluation of Safety and Efficacy of Shorttime TNI Treatment in Patients with COPD Acute testing of oxygen demand using TNI vs. standard oxygen application in stable COPD patients An investigator-initiated, prospective, controlled, multicenter study Read more about this study
- Who is it for?
- Ages 30 to 80 years
- Conditions the study is for
- Oxygen Inhalation Therapy
- What is being tested?
- Nasal oxygen insufflation with a TNI 20 oxy device and Standard Nasal Insufflation of oxygen
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 3 sitesin 3 countries
- Study dates
- Feb 2009to Mar 2013
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- COPD patients with an indication for long-term oxygen therapy Age 30 - 80 years COPD GOLD °III
Who cannot join
- Clinical instability of the patient No lung function testing possible Exacerbation within the last 14 days prior to inclusion into the study Serious concomitant diseases that may jeopardize the inclusion of the patient into the study from the investigator's point of view Anaemia, defined by a haemoglobin <10 G/L Patients with hypercapnia, defined by a paCO <46mmHg Participation of the patient in any other ongoing study
Trial locations and contacts
3 sites in 3 countries.
3 sites in 3 countries
Austria1 site, 1 recruiting
- Recruiting
Pneumology/USPH Innsbruck, Medical University Innsbruck
Innsbruck, A-6020
Christian M Kaehler, MD, 004351250423255, c.m.kaehler@i-med.ac.at
Germany1 site, 1 recruiting
- Recruiting
Pneumologie, Medizinische Klinik und Poliklinik I, University Dresden
Dresden, D-01307
Michael Halank, MD, 0049 351 458 4721
Gert Höffken, MD
Switzerland1 site, 1 recruiting
- Recruiting
Klinik und Poliklinik für Pneumologie, Inselspital, Universitätsspital Bern
Bern, CH-3010
Thomas Geiser, MD, 0031 632 34 90
About this study
Official title: STIT-1 Evaluation of Safety and Efficacy of Shorttime TNI Treatment in Patients With COPD
Evaluation of Safety and Efficacy of Shorttime TNI Treatment in Patients with COPD Acute testing of oxygen demand using TNI vs. standard oxygen application in stable COPD patients An investigator-initiated, prospective, controlled, multicenter study
Read the detailed description
TNI, the nasal insufflation of a high flow of warm, humidified air, is an extremely comfortable and uncomplicated alternative to numerous other approaches in non-invasive ventilation (NIV). Up to now, NIV therapy could only be applied by masks with the associated complications as patients could not tolerate high airflow delivered by a thin nasal cannula without humidification and warming, thus causing concomitant negative effects. The new therapy TNI shows a high rate of acceptance by children, too.
At present, there are two different types of devices available for nasal insufflation in clinics:
TNI 20s, an air humidifier for clinical compressed air, and the TNI20 oxy, an air humidifier for clinical compressed air, which can be combined with oxygen.
TNI 20 oxy The system, which is unique throughout the world, is optimized for the application of flows of up to 20L/min and fulfils the minimum requirements of the "American Society of Testing and Materials" for a high flow air humidifier in the non-invasive application of 10 mg H2O/L (equivalent to about 60% rel. humidity at an ambient temperature of 22°C) for the air humidity. The warming of the air flow by 5-15°C can be adjusted relative to the ambient temperature. Condensation is prevented in the nasal applicator by heating the tube as far as the nostrils. The device automatically controls humidity and temperature depending on the prevailing ambient conditions. The TNI®20s can be attached to the hospital infrastructure by means of a standard pressure regulator.
- Conditions
- Oxygen Inhalation Therapy
- Being tested
- Nasal oxygen insufflation with a TNI 20 oxy device, Standard Nasal Insufflation of oxygen
- Keywords
- Oxygen, Insufflation, COPD, High Flow Treatment
- Medical subject headings
- Pulmonary Disease, Chronic Obstructive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nasal oxygen insufflation with a TNI 20 oxy deviceDevice
Also called TNI 20 oxy
Nasal oxygen insufflation with a TNI 20 oxy device
Standard Nasal Insufflation of oxygenDevice
Standard Nasal Insufflation of oxygen
| Study group | Role | What they receive |
|---|---|---|
| Standard Nasal Insufflation of oxygen | Active comparator | Standard Nasal Insufflation of oxygen Receives: Device: Standard Nasal Insufflation of oxygen |
| Nasal oxygen insufflation with a TNI 20 oxy device | Active comparator | Nasal oxygen insufflation with a TNI 20 oxy device Receives: Device: Nasal oxygen insufflation with a TNI 20 oxy device |
What is being measured
The primary outcome is the main question the study is designed to answer.
PaO2
Change in the partial oxygen pressure in the arterial blood (blood gas analysis) at a defined oxygen flow rate (L/min)
Measured: Measures at Baseline and after 60 min
Secondary outcomes (4)
O2 %
Change in the oxygen saturation in the arterial blood (blood gas analysis) at a defined oxygen flow rate (L/min)
Measured: Measures at Baseline and after 60 min
PaCO2
Change in the partial carbon dioxide pressure in the arterial blood (blood gas analysis) at a defined oxygen flow rate (L/min)
Measured: Measures at Baseline and after 60 min
AaDO2
Change in the AaDO2 in the peripheral blood at a defined oxygen flow rate (L/min)
Measured: Measures at Baseline and after 60 min
RV and TLC
Safety of the device in COPD °III or IV patients:
No increase in the residual volume (RV) and the total lung capacity (TLC) > 15% of the mean actual value at visits 1 and 2 (measurement 60 + 10 minutes after oxygen insufflation with a TNI system).
Measured: Measures at Baseline and after 60 min
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Sep 2012 (estimated)
- Study startFeb 2009
- Primary completionFeb 2013 (estimated)
- Study completionMar 2013 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Oxygen Inhalation TherapyStudies of the same condition, open and under way.
- More trials run by Medical University InnsbruckThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Medical University Innsbruck
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Univ.-Prof. Dr. Christian M. Kaehler, Medical University Innsbruck
- Investigators
- Christian M Kaehler, MD, Principal investigator, Pneumology, Medical University Innsbruck
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01686893
- Sponsor's protocol ID
- AN3547
- Other IDs
- AN 3546
- Acronym
- STIT-1
- Status last verified
- Sep 2012
- First submitted
- 13 Sep 2012
- Last updated
- 19 Sep 2012
- Results posted
- No
- Data monitoring committee
- No
Publications
Vogelsinger H, Halank M, Braun S, Wilkens H, Geiser T, Ott S, Stucki A, Kaehler CM. Efficacy and safety of nasal high-flow oxygen in COPD patients. BMC Pulm Med. 2017 Nov 17;17(1):143. doi: 10.1186/s12890-017-0486-3.
PubMed 29149867
Study at a glance
From the registry record, last updated by the sponsor on 19 Sep 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- STIT-1 Evaluation of Safety and Efficacy of Shorttime TNI Treatment in Patients With COPD
- ClinicalTrials.gov ID
- NCT01686893
- Acronym / sponsor ID
- STIT-1 / AN3547
- Conditions
- Oxygen Inhalation Therapy
- Keywords
- Oxygen, Insufflation, COPD, High Flow Treatment
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Medical University InnsbruckUniversity, hospital or other
- Study start
- Feb 2009
- Primary completion
- Feb 2013 (estimated)
- Study completion
- Mar 2013 (estimated)
- First posted
- 18 Sep 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Evaluation of Safety and Efficacy of Shorttime TNI Treatment in Patients with COPD Acute testing of oxygen demand using TNI vs. standard oxygen application in stable COPD patients An investigator-initiated, prospective, controlled, multicenter study
Detailed description
TNI, the nasal insufflation of a high flow of warm, humidified air, is an extremely comfortable and uncomplicated alternative to numerous other approaches in non-invasive ventilation (NIV). Up to now, NIV therapy could only be applied by masks with the associated complications as patients could not tolerate high airflow delivered by a thin nasal cannula without humidification and warming, thus causing concomitant negative effects. The new therapy TNI shows a high rate of acceptance by children, too.
At present, there are two different types of devices available for nasal insufflation in clinics:
TNI 20s, an air humidifier for clinical compressed air, and the TNI20 oxy, an air humidifier for clinical compressed air, which can be combined with oxygen.
TNI 20 oxy The system, which is unique throughout the world, is optimized for the application of flows of up to 20L/min and fulfils the minimum requirements of the "American Society of Testing and Materials" for a high flow air humidifier in the non-invasive application of 10 mg H2O/L (equivalent to about 60% rel. humidity at an ambient temperature of 22°C) for the air humidity. The warming of the air flow by 5-15°C can be adjusted relative to the ambient temperature. Condensation is prevented in the nasal applicator by heating the tube as far as the nostrils. The device automatically controls humidity and temperature depending on the prevailing ambient conditions. The TNI®20s can be attached to the hospital infrastructure by means of a standard pressure regulator.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Standard Nasal Insufflation of oxygen | Active comparator | Device: Standard Nasal Insufflation of oxygenStandard Nasal Insufflation of oxygen |
| Nasal oxygen insufflation with a TNI 20 oxy device | Active comparator | Device: Nasal oxygen insufflation with a TNI 20 oxy deviceNasal oxygen insufflation with a TNI 20 oxy device |
Who may qualify
- Ages
- 30 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- COPD patients with an indication for long-term oxygen therapy Age 30 - 80 years COPD GOLD °III
Key exclusion criteria (1 listed)
- Clinical instability of the patient No lung function testing possible Exacerbation within the last 14 days prior to inclusion into the study Serious concomitant diseases that may jeopardize the inclusion of the patient into the study from the investigator's point of view Anaemia, defined by a haemoglobin <10 G/L Patients with hypercapnia, defined by a paCO <46mmHg Participation of the patient in any other ongoing study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nasal oxygen insufflation with a TNI 20 oxy deviceAlso: TNI 20 oxyNasal oxygen insufflation with a TNI 20 oxy device | Device | Nasal oxygen insufflation with a TNI 20 oxy device |
| Standard Nasal Insufflation of oxygenStandard Nasal Insufflation of oxygen | Device | Standard Nasal Insufflation of oxygen |
Primary outcome
PaO2
Time frame: Measures at Baseline and after 60 min
Change in the partial oxygen pressure in the arterial blood (blood gas analysis) at a defined oxygen flow rate (L/min)
4 secondary outcomes
O2 %
Time frame: Measures at Baseline and after 60 min
PaCO2
Time frame: Measures at Baseline and after 60 min
AaDO2
Time frame: Measures at Baseline and after 60 min
RV and TLC
Time frame: Measures at Baseline and after 60 min
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Sep 2012.
- Derived from this study: PubMed 29149867Vogelsinger H, Halank M, Braun S, Wilkens H, Geiser T, Ott S, Stucki A, Kaehler CM. Efficacy and safety of nasal high-flow oxygen in COPD patients. BMC Pulm Med. 2017 Nov 17;17(1):143. doi: 10.1186/s12890-017-0486-3.
Related trials for Oxygen Inhalation Therapy
Not yet recruitingObservational study
"Comparison of Oxygen Reserve Index (ORI), End-Tidal Oxygen, and Time-Based Preoxygenation Targets With Arterial Blood Gas During Preoxygenation
Preoxygenation Adequacy Assessed by Oxygen Reserve Index, End-tidal Oxygen and Arterial Blood Gas
RecruitingObservational study
Development and Validation of a Multimodal Deep Learning Model Using Peripheral Oxygen Saturation and Ballistocardiography Signals for Predicting Apnea-Hypopnea Index in Obstructive Sleep Apnea
Obstructive Sleep Apnea
Recruiting
Optimization of Saturation Targets And Resuscitation Trial (OptiSTART)
Premature Infants, Bronchopulmonary Dysplasia
Not yet recruitingPhase 2
Supplemental Oxygen for Sleep-Disordered Breathing in Adults With Chronic Opioid Use.
Sleep-disordered Breathing, Chronic Opioid Use
Not yet recruiting
Effects of Oxygen Cage Support During Cataract Surgery
Cataract
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Christian M Kaehler, MD principal investigator
Pneumology, Medical University Innsbruck
3 sites in 3 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Nasal oxygen insufflation with a TNI 20 oxy device and Standard Nasal Insufflation of oxygen in people with Oxygen Inhalation Therapy, run by Medical University Innsbruck at 3 sites in 3 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 19 Sep 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Austria, Germany, Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Christian M Kaehler, MD (004351250423255, c.m.kaehler@i-med.ac.at), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
PaO2 (time frame: Measures at Baseline and after 60 min). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01686893, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Sep 2012.